Equities
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)6,383.00
  • Today's Change-1.00 / -0.02%
  • Shares traded1.63m
  • 1 Year change+31.99%
  • Beta0.8694
Data delayed at least 20 minutes, as of Nov 21 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.

  • Revenue in JPY (TTM)1.14tn
  • Net income in JPY386.96bn
  • Incorporated1943
  • Employees7.60k
  • Location
    Chugai Pharmaceutical Co Ltd15F, Nihonbashi Mitsui Tower2-1-1, Nihonbashi-Muro-machiCHUO-KU 103-8324JapanJPN
  • Phone+81 332816611
  • Fax+81 332812828
  • Websitehttps://www.chugai-pharm.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Haleon PLC2.21tn237.55bn6.56tn24.00k17.50--177.502.970.21060.21061.44--------468,333.30--------61.94--11.21----7.59----4.09---1.04------
Takeda Pharmaceutical Co Ltd4.55tn289.99bn6.65tn49.28k22.990.95796.341.46181.90181.902,862.684,365.910.30881.316.2592,248,190.001.971.652.351.9766.0568.056.386.060.77393.080.4219128.425.8715.25-54.561.2829.090.8735
Jiangsu Hengrui Pharmaceuticals Co Ltd557.63bn116.87bn6.90tn19.61k59.377.35--12.380.84990.84994.066.860.571.574.601,325,555.0011.9413.6812.9915.2084.8885.8720.9420.018.34--0.00223.777.265.5510.141.1422.909.45
Sun Pharmaceutical Industries Ltd926.88bn203.66bn7.86tn43.00k38.546.1731.158.4846.1246.12209.89288.060.60051.054.1511,699,470.0013.297.7716.9210.8579.1571.5922.1414.232.09--0.035838.6410.5110.7813.0129.15-7.2837.47
Daiichi Sankyo Co Ltd1.76tn250.40bn8.77tn18.73k34.405.2627.824.99130.86130.86918.60855.860.59131.013.7393,883,960.008.434.9910.516.1476.1169.1014.269.942.24--0.058951.8725.2811.4985.9016.6713.0116.47
Merck KGaA3.44tn441.85bn9.84tn62.26k22.252.1213.272.866.216.2148.2565.140.41911.854.98333,232.705.415.646.707.2758.6061.8612.9012.970.910354.780.28619.26-5.577.19-15.0921.4014.7711.97
GSK plc6.16tn493.78bn10.60tn70.21k21.343.799.611.720.60930.60937.623.430.52661.513.93445,949.404.796.747.4810.7172.4470.299.1016.930.530313.080.544279.553.42-0.32215.797.105.47-10.32
Chugai Pharmaceutical Co Ltd1.14tn386.96bn10.72tn7.60k27.155.83--9.38235.14235.14694.161,094.710.58771.223.56150,230,100.0019.9119.2922.9523.9170.4863.5733.8728.394.80--0.0040.14-11.7813.90-13.0828.61-0.894727.23
Zoetis Inc1.42tn377.71bn12.32tn14.10k33.0315.1626.988.665.325.3220.0211.590.64311.066.86649,078.0017.1314.4719.3817.1870.1369.7726.6425.772.2718.960.556726.895.747.9610.8811.1316.7124.37
CSL Ltd2.29tn409.06bn13.43tn30.40k32.894.9923.755.868.348.3446.7055.010.39861.255.80745,482.207.319.468.9511.7051.8353.8418.3420.110.97058.740.385746.7011.1911.6320.426.61-0.42077.26
Data as of Nov 21 2024. Currency figures normalised to Chugai Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

11.68%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 07 Nov 202450.15m2.99%
Nikko Asset Management Co., Ltd.as of 08 Nov 202424.32m1.45%
The Vanguard Group, Inc.as of 06 Nov 202422.97m1.37%
Daiwa Asset Management Co. Ltd.as of 31 Oct 202422.56m1.34%
Wellington Management Co. LLPas of 31 Oct 202420.16m1.20%
BlackRock Fund Advisorsas of 07 Nov 202414.84m0.88%
Mitsubishi UFJ Asset Management Co., Ltd.as of 07 Nov 202412.44m0.74%
Harding Loevner LPas of 30 Sep 202410.15m0.61%
T. Rowe Price Associates, Inc. (IM)as of 30 Sep 20249.92m0.59%
Norges Bank Investment Managementas of 30 Jun 20248.61m0.51%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.